Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28458597 | 1.00 | HCRTR2 (0.41) | HCRTR2EPHX1TDP1DRD2BTK | |
| SCHEMBL28662052 | 0.87 | HCRTR2 (0.45) | HCRTR2EPHX1TDP1KMT2AMEN1 | |
| SCHEMBL28662054 | 0.87 | HCRTR2 (0.45) | HCRTR2EPHX1TDP1KMT2AMEN1 | |
| SCHEMBL21607409 | 0.84 | HCRTR2 (0.39) | HCRTR2EPHX1TDP1DRD2BTK | |
| SCHEMBL21607408 | 0.84 | HCRTR2 (0.39) | HCRTR2EPHX1TDP1DRD2BTK | |
| SCHEMBL21607705 | 0.84 | HCRTR2 (0.39) | HCRTR2EPHX1TDP1DRD2BTK | |
| SCHEMBL28532985 | 0.84 | HCRTR2 (0.39) | HCRTR2EPHX1TDP1DRD2BTK | |
| SCHEMBL8286393 | 0.84 | DRD2 (0.39) | HCRTR2EPHX1TDP1DRD2KMT2A | |
| SCHEMBL21607699 | 0.84 | HCRTR2 (0.39) | HCRTR2EPHX1TDP1DRD2BTK | |
| SCHEMBL2750096 | 0.84 | HCRTR2 (0.47) | HCRTR2EPHX1TDP1DRD2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975037-B2 | Phenyl substituted pyrazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| WO-2019243999-A1 | PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975037-B2 | Phenyl substituted pyrazoles as modulators of RORγt | RORC, RORB, RORA | HCRTR2 981/4885EPHX1 1753/4885TDP1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.